Is MDAI a Buy? What to Consider in 2026
Short answer
The bull case for Spectral AI (MDAI) rests on FDA clearance opens the U.S. market: In May 2026 Spectral AI received FDA De Novo clearance for the DeepView System's burn indication, the regulatory milestone the company had worked toward for years. Revenue (FY2025, mostly research/BARDA) is ~$19.7 million R&D revenue, down from ~$29.6 million in 2024. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The risks are substantial and concentrated. Whether MDAI is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Spectral AI, Inc. (NASDAQ: MDAI), based in Dallas, Texas, is an artificial-intelligence medical-technology company focused on wound care. Its flagship DeepView System uses multispectral imaging and a proprietary deep-learning algorithm to assess the healing potential of burns and other wounds, delivering an AI-driven tissue classification in roughly 20 to 25 seconds after a sub-second image capture, without touching the patient. The algorithm was trained and validated on a large proprietary database of clinically labeled burn-wound images. The goal is to give clinicians in burn centers, trauma centers, and emergency departments an objective read on which tissue will heal on its own and which requires surgical intervention, a judgment that has traditionally relied on subjective visual inspection. Spectral AI became a public company in 2023 via a SPAC merger and has been development-stage for essentially its entire history. Since 2013 it has been awarded roughly $282.5 million in government funding, the large majority from BARDA (the U.S. Biomedical Advanced Research and Development Authority) under a Project BioShield contract valued up to $150 million, with additional U.S. Department of Defense funding supporting a handheld Snapshot module. That government money, booked as research-and-development revenue, has funded most of the company's work. On the regulatory path, Spectral AI submitted a De Novo application to the FDA in June 2025 and received FDA De Novo clearance for the DeepView System's burn indication in May 2026, authorizing U.S. commercial distribution. The financial reality remains stark: full-year 2025 R&D revenue was about $19.7 million (down from $29.6 million) with a net loss of roughly $7.6 million, cash was about $15.4 million at year-end 2025 and around $11.7 million by March 31, 2026, and the company has relied on equity, warrants, and debt to fund operations as it shifts toward commercialization.
What's the case for buying MDAI?
1. FDA clearance opens the U.S. market.
In May 2026 Spectral AI received FDA De Novo clearance for the DeepView System's burn indication, the regulatory milestone the company had worked toward for years. Clearance authorizes commercial distribution in the United States and is the gate to any meaningful product revenue. Management has signaled it hopes to begin commercializing DeepView by the end of 2026 and is working with Deloitte Consulting on its go-to-market strategy. The opportunity now shifts from getting approved to actually selling and getting reimbursed.
2. Non-dilutive government funding.
Spectral AI's development has been financed largely by government contracts, with roughly $282.5 million awarded since 2013, the bulk from BARDA. The company highlighted $31.7 million in advanced, non-dilutive BARDA funding tied to an accelerated phase of its Project BioShield contract, plus DoD support for a handheld module. This funding has let it build the technology with far less shareholder dilution than a typical pre-revenue device company, though it also means most reported revenue is reimbursed research cost, not commercial sales.
3. Large clinical and addressable need.
Assessing burn depth and wound healing is notoriously subjective, and accurate early triage can change whether a patient needs surgery. DeepView aims to standardize that judgment with an objective AI read at the bedside. Beyond initial burn use in burn, trauma, and emergency settings, the company has discussed extending the platform to chronic wounds such as diabetic foot ulcers, a far larger long-term market if the technology proves out and earns its own clearances.
4. Commercial build-out underway.
With clearance in hand, Spectral AI is assembling commercial infrastructure: it has been searching for a chief commercial officer, engaged outside consultants on launch strategy, and continued developing a more portable Snapshot module funded by the DoD. Whether these steps convert into installed systems, recurring usage, and reimbursement is the central unknown. Management has guided that 2026 revenue stays roughly flat at about $18.5 million, mostly BARDA-funded, with 2027 and 2028 framed as the intended growth years.
What are the risks to MDAI?
The risks are substantial and concentrated. Even with De Novo clearance, commercialization risk is high: Spectral AI has almost no track record of selling product, and revenue, hospital adoption, and reimbursement for a novel AI imaging device are all unproven. The company depends heavily on government funding, so changes to BARDA or DoD contracts could sharply reduce the revenue it reports today. It is unprofitable and burns cash, with only about $11.7 million on hand at March 31, 2026 against ongoing losses, which makes further dilution through equity, warrants (MDAIW), or debt likely. As a micro-cap with roughly 31.8 million shares and a market value frequently in the tens of millions, the stock is thinly traded and highly volatile, and it faces competition from other wound-imaging and AI-diagnostics approaches as well as the inertia of standard visual assessment.
How is MDAI valued? (as of FY2025 results and Q1 2026 (reported May 2026))
- Revenue (FY2025, mostly research/BARDA): ~$19.7 million R&D revenue, down from ~$29.6 million in 2024
- Net loss (FY2025): ~$7.6 million net loss for the full year
- Revenue (Q1 2026): ~$4.0 million, down ~40% year over year as BARDA work shifted phases
- Net loss (Q1 2026): ~$3.4 million, versus net income of ~$2.9 million a year earlier
- Cash: ~$15.4 million at Dec 31, 2025; ~$11.7 million at Mar 31, 2026
- Market cap / shares: ~$58 million to $74 million in 2026 (highly volatile); ~31.8 million shares outstanding
- Dividend yield: 0%; Spectral AI does not pay a dividend
Spectral AI should be read as a pre-commercial, development-stage company rather than a normal operating business. Almost all of its reported revenue is research-and-development funding reimbursed under government contracts, chiefly BARDA, so the top line reflects grant-funded development rather than product sales, and it can fall when a contract phase completes (as it did in Q1 2026). Earnings are negative and lumpy, so a P/E ratio is not meaningful, and the market cap reflects expectations for commercializing DeepView, not current profits. All figures are approximate as of the dates noted and change each quarter; verify against Spectral AI's investor relations page or your broker.
How do you decide if MDAI is a buy?
Rather than asking whether MDAI is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MDAI indirectly through an index or sector ETF before adding more.
For the full picture, see the MDAI stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MDAI against your real portfolio and see your actual exposure before deciding.
The bottom line on MDAI
The bottom line: Spectral AI's story right now is FDA clearance opens the U.S. market, with revenue (fy2025, mostly research/barda) at ~$19.7 million R&D revenue, down from ~$29.6 million in 2024. If you believe that narrative continues, the call is about sizing MDAI sensibly and checking overlap with what you own; if you doubt it (the risk: the risks are substantial and concentrated.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around MDAI with Walnut
Use Spectral AI as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MDAI a good stock to buy right now?
+
The case for Spectral AI right now is FDA clearance opens the U.S. market, with revenue (fy2025, mostly research/barda) at ~$19.7 million R&D revenue, down from ~$29.6 million in 2024. If you believe that thesis holds, MDAI is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the risks are substantial and concentrated. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Spectral AI do?
+
Medical-AI company whose DeepView System uses multispectral imaging and AI to predict burn and wound healing potential, pre-commercial and funded largely by BARDA and DoD contracts.
What are the main risks of MDAI?
+
The risks are substantial and concentrated. Even with De Novo clearance, commercialization risk is high: Spectral AI has almost no track record of selling product, and revenue, hospital adoption, and reimbursement for a novel AI imaging device are all unproven. The company depends heavily on government funding, so changes to BARDA or DoD contracts could sharply reduce the revenue it reports today. It is unprofitable and burns cash, with only about $11.7 million on hand at March 31, 2026 against ongoing losses, which makes further dilution through equity, warrants (MDAIW), or debt likely. As a micro-cap with roughly 31.8 million shares and a market value frequently in the tens of millions, the stock is thinly traded and highly volatile, and it faces competition from other wound-imaging and AI-diagnostics approaches as well as the inertia of standard visual assessment.
What does Spectral AI do?
+
Spectral AI is a medical-technology company whose DeepView System uses multispectral imaging and a proprietary AI algorithm to assess the healing potential of burns and wounds. It produces an objective, non-contact tissue classification in roughly 20 to 25 seconds, intended to help clinicians in burn centers, trauma centers, and emergency departments decide which tissue will heal on its own and which needs surgery. The company has been funded largely by U.S. government research contracts.
What is DeepView?
+
DeepView is Spectral AI's flagship system. It captures a sub-second multispectral image of a wound and runs a deep-learning algorithm, trained on a large proprietary database of clinically labeled burn images, to predict healing potential without touching the patient. The output aims to replace subjective visual judgment of burn depth with an objective, AI-driven read. A handheld Snapshot version is also in development with U.S. Department of Defense funding.
What is MDAI's FDA status and how is it funded?
+
Spectral AI submitted a De Novo application to the FDA in June 2025 and received FDA De Novo clearance for the DeepView System's burn indication in May 2026, authorizing U.S. commercial distribution. Its development has been funded largely by government contracts, around $282.5 million awarded since 2013, mostly from BARDA under a Project BioShield contract, plus DoD support. That funding is booked as research revenue, so most of the company's reported revenue has come from grants rather than product sales.
Does MDAI pay a dividend?
+
No. Spectral AI does not pay a dividend, so its yield is 0%. As a pre-commercial, unprofitable company that burns cash and reinvests in development and commercialization, it is not an income stock; any return would come from share-price changes rather than dividends. This is current as of the dates noted; verify against Spectral AI's investor relations page.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MDAI; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.